Skip to main navigation Skip to search Skip to main content

PHASE III TRIAL DATA SUPPORT CURRENT STANDARD 12-MONTH ADJUVANT TRASTUZUMAB FOR HER2-POSITIVE BREAST CANCER NINE WEEKS OF TRASTUZUMAB MAY BE SUFFICIENT FOR PATIENTS WHO RECEIVE HIGHER DOSE OF DOCETAXEL

Press/Media: Press / Media

Period7 Dec 2017

Media coverage

1

Media coverage

  • TitlePHASE III TRIAL DATA SUPPORT CURRENT STANDARD 12-MONTH ADJUVANT TRASTUZUMAB FOR HER2-POSITIVE BREAST CANCER NINE WEEKS OF TRASTUZUMAB MAY BE SUFFICIENT FOR PATIENTS WHO RECEIVE HIGHER DOSE OF DOCETAXEL
    Media name/outletStates News Service
    Country/TerritoryUnited States
    Date07/12/2017
    PersonsHeikki Joensuu
View all 1
View less